Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
BRISBANE, Calif., Nov. 08, 2016 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Dr. Peter Maag, Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be participating in four upcoming investor conferences:
Mizuho Global Investor Conference in New York City
- Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on Monday, November 14, 2016
7th Annual Craig-Hallum Alpha Select Conference in New York City
- Dr. Peter Maag and Charles Constanti will present on Wednesday, November 16, 2016 at 11:50am PT/2:50pm ET.
28th Annual Piper Jaffray Healthcare Conference in New York City
- Dr. Peter Maag and Charles Constanti will present on Tuesday, November 29, 2016 at 11:00am PT/1:00pm ET.
Evercore ISI MedTools Investor Conference in Boston, MA
- Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on December 1, 2016.
A live audio webcast of the Craig-Hallum Alpha Select and Piper Jaffray Healthcare conferences presentations will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of each presentation will be available on the Company's website for 90 days. Due to the one-on-one only format of the Mizuho and Evercore ISI MedTools conferences, no webcasts will be available.
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying risk of rejection in heart transplant recipients.
CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. For more information, please visit: www.CareDx.com.
Investor Relations Contact Jamar Ismail, Vice President Westwicke Partners, LLC T: +1 415-513-1282 E: [email protected]
